Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, April 14, 2017 1:25:05 PM
by Eric Sagonowsky | Feb 21, 2017 4:30pm
http://www.fiercepharma.com/vaccines/flu-vaccines-48-effective-so-far-season-cdc-says
So far this season, flu vaccines have been 48% effective in preventing medical visits, according to a CDC estimate.
This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season. But, as of data ending Feb. 4, government experts don’t expect the season to come to a close right away.
CDC anticipates “several more weeks” of flu activity in parts of the U.S., according to an agency update. So far, vaccines have been 48% effective in preventing flu-related medical visits, the CDC estimates.
That compares to 59% for last year and 19% for the year before, according to the CDC. Over 10 previous flu seasons, vaccine effectiveness has fluctuated each year, often ending up with a percentage in the 40s or 50s.
Separately this year, CDC experts recommended against any use of AstraZeneca’s FluMist on efficacy concerns from three previous seasons. AZ said it’s working to assess the situation.
All year round, experts monitor the virus and select strains for the upcoming season. But, in an effort to improve on so-so efficacy and avoid strain drift, several biopharma companies are working on “universal” vaccines that fight a range of strains over multiple years.
Sanofi, the world’s largest flu vaccine manufacturer, in late 2015 unveiled its work in the area. It announced a vax project dubbed Cobra that’s designed to protect against multiple strains by using common sequences the strains share.
Other companies and groups that have gotten into universal flu vaccine work include Johnson & Johnson’s Crucell and Scripps Research Institute, plus biotechs BiondVax and FluGen.
Recent BVXV News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/07/2023 09:27:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 04:01:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 03:44:03 PM
- BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics • GlobeNewswire Inc. • 09/06/2023 10:00:00 AM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 08/28/2023 08:01:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/28/2023 04:15:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/24/2023 08:05:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2023 10:10:14 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/18/2023 08:16:19 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/18/2023 02:07:35 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/14/2023 10:08:59 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/11/2023 01:44:48 PM
- BiondVax Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/11/2023 01:00:00 PM
- Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules • GlobeNewswire Inc. • 08/01/2023 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2023 08:00:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2023 07:10:31 PM
- IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. • GlobeNewswire Inc. • 07/11/2023 12:17:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/05/2023 01:17:40 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM